Dashboard
Manage Tickers

GLMD


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
10/13/2025 21:06:47

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/07/2025 12:08:21

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/11/2025 21:06:02

galmed-pharmaceuticals-q2-eps-063-beats-083-estimate
Galmed Pharmaceuticals Q2 EPS $(0.63) Beat...
08/28/2025 13:36:46

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate o...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/28/2025 12:08:20

galmed-board-approves-digital-asset-management-strategy-including-potential-allocation-of-up-to-50-of-cash-reserves-to-be-used-for-digital-asset-purchases
Galmed Board Approves Digital Asset Manage...
08/25/2025 11:37:58

why-palo-alto-shares-are-trading-higher-by-around-7-here-are-20-stocks-moving-premarket
Why Palo Alto Shares Are Trading Higher By...
08/19/2025 12:01:09

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
06/20/2025 12:09:39

galmed-pharma-announces-discovery-of-proprietary-pd-blood-based-biomarker-signature-for-aramchol-clinically-advanced-stearoyl-coa-desaturase-1-inhibitor
Galmed Pharma Announces Discovery Of Propr...
05/27/2025 12:03:49

Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic ...

galmed-pharmaceuticals-q1-eps-062-beats-089-estimate
Galmed Pharmaceuticals Q1 EPS $(0.62) Beat...
05/22/2025 12:13:51

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate o...

galmed-pharma-first-set-of-oncology-studies-show-aramchol-enhances-liver--colorectal-cancer-approved-therapeutic-regorafenib-effects-in-liver-and-colon-cancers-in-vitro-and-in-vivo-models
Galmed Pharma: First Set Of Oncology Studi...
05/06/2025 11:39:03

Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combinati...

crude-oil-down-2-roper-technologies-increases-2025-outlook
Crude Oil Down 2%; Roper Technologies Incr...
04/28/2025 16:38:56

dow-jumps-over-150-points-dominos-pizza-posts-upbeat-earnings
Dow Jumps Over 150 Points; Domino's Pizza ...
04/28/2025 13:56:16

galmed-pharmaceuticals--enters-sponsored-project-agreement-with-virginia-commonwealth-university-to-evaluate-aramchols-effect-on-overcoming-drug-resistance-in-gastrointestinal-cancers
Galmed Pharmaceuticals Enters Sponsored P...
04/17/2025 12:33:21

Galmed Pharmaceuticals (NASDAQ:GLMD) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to e...

galmed-unveils-pharmacodynamic-blood-markers-for-aramchol
Galmed Unveils Pharmacodynamic Blood Marke...
04/15/2025 12:32:45

Analysis of blood samples from patients treated with Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights int...

galmed-announces-part-1-results-from-am-001-study-of-aramchol-meglumine-an-enhanced-formulation-of-the-most-clinically-advanced-scd1-inhibitor
Galmed Announces Part 1 Results From AM-00...
04/10/2025 12:06:12

– AM-001 Study represents a pivotal milestone in Galmed's transition to Aramchol Meglumine, an improved formulation of its ...

maxim-group-downgrades-galmed-pharmaceuticals-to-hold
Maxim Group Downgrades Galmed Pharmaceutic...
04/04/2025 13:20:41

Maxim Group analyst Naz Rahman downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Buy to Hold.

galmed-pharmaceuticals-files-annual-report-on-form-20-f-for-fiscal-year-ended-december-31-2024
Galmed Pharmaceuticals Files Annual Report...
04/02/2025 20:15:16

TEL AVIV, Israel, April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ('Galmed' or the 'Company...

galmed-pharmaceuticals-announces-the-grant-of-a-new-patent-related-to-aramchol-patent-covers-the-use-of-a-combination-therapy-of-aramchol-and-resmetirom-for-the-treatment-of-non-alcoholic-steatohepatitis-also-known-as-metabolic-dysfunction-associated-steatohepatitis-and-liver-fibrosis
Galmed Pharmaceuticals Announces The Grant...
03/20/2025 12:57:54

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical compa...

galmed-pharmaceuticals-shares-resumed-trade
Galmed Pharmaceuticals Shares Resumed Trade
03/17/2025 13:43:46

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION